Literature DB >> 24462552

Differential expression and localization of neuropeptide Y peptide in pancreatic islet of diabetic and high fat fed rats.

Zheng Ruipan1, Meng Xiangzhi1, Liu Li1, Zhang Ying1, Qiao Mingliang1, Jing Peng1, Liu Jingwei1, Zhao Zijun1, Gao Yan2.   

Abstract

Neuropeptide Y (NPY) inhibits insulin secretion. Increased numbers of pancreatic islet cells expressing NPY have been observed in type 1 diabetic rats. To understand the functional significance of NPY expression in islet cells, we investigated the effects of high fat feeding and diabetic conditions on the expression and location of NPY expressing cells in normal and diabetic rats. Twenty rats were maintained on either normal chow (ND) or a high fat dietary regimen (HFD) for 4 weeks. In half of each group, type 1 or type 2 diabetes (groups T1DM and T2DM, respectively) was induced by injection of streptozotocin. At 8 weeks rats were euthanized and the pancreases were processed for immunofluorescence labeling (NPY/insulin, NPY/glucagon, NPY/somatostatin, and NPY/pancreatic polypeptide). Compared with the ND group, HFD rats had significantly fewer alpha cells, but beta cells were similar, while T1DM and T2DM rats showed significant increases in the proportions of alpha, delta, and PP cells. Robust increases in NPY-positive islet cells were found in the HFD, T1DM, and T2DM rats compared with ND controls. In ND rats, 99.7% of the NPY-positive cells were PP cells. However, high fat feeding and diabetes resulted in significant increases in NPY-positive delta cells, with concomitant decreases in NPY-positive PP cells. In summary, high-fat feeding and diabetes resulted in changes in the hormonal composition of pancreatic islet and increased number of NPY-expressing islet cells. Under diabetic conditions NPY expression switched from predominantly a characteristic of PP cells to predominantly that of delta cells. This may be a factor in reduced pancreatic hormone secretion during diabetes.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes mellitus; High-fat diet; Islet; Neuropeptide Y; STZ

Mesh:

Substances:

Year:  2014        PMID: 24462552     DOI: 10.1016/j.peptides.2014.01.003

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  5 in total

1.  Neuropeptide Y genotype, central obesity, and abdominal fat distribution: the POUNDS LOST trial.

Authors:  Xiaochen Lin; Qibin Qi; Yan Zheng; Tao Huang; Mark Lathrop; Diana Zelenika; George A Bray; Frank M Sacks; Liming Liang; Lu Qi
Journal:  Am J Clin Nutr       Date:  2015-07-08       Impact factor: 7.045

Review 2.  Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome.

Authors:  Teodor T Postolache; Laura Del Bosque-Plata; Serge Jabbour; Michael Vergare; Rongling Wu; Claudia Gragnoli
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2019-02-06       Impact factor: 3.568

3.  Pancreatic islet neuropeptide Y overexpression has minimal effect on islet morphology and β-cell adaptation to high-fat diet.

Authors:  Yui Machida; Christine Bruinsma; Daniel R Hallinger; Stephen M Roper; Eden Garcia; Michelle B Trevino; Joseph Nadler; Rexford Ahima; Yumi Imai
Journal:  Endocrinology       Date:  2014-10-06       Impact factor: 4.736

4.  Peripherally Administered Y2-Receptor Antagonist BIIE0246 Prevents Diet-Induced Obesity in Mice With Excess Neuropeptide Y, but Enhances Obesity in Control Mice.

Authors:  Liisa Ailanen; Laura H Vähätalo; Henriikka Salomäki-Myftari; Satu Mäkelä; Wendy Orpana; Suvi T Ruohonen; Eriika Savontaus
Journal:  Front Pharmacol       Date:  2018-04-05       Impact factor: 5.810

Review 5.  Metallothionein-3 as a multifunctional player in the control of cellular processes and diseases.

Authors:  Jae-Young Koh; Sook-Jeong Lee
Journal:  Mol Brain       Date:  2020-08-25       Impact factor: 4.041

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.